Dublin, Ireland-based Horizon Pharma plc is a biopharmaceutical focused on identifying, developing, acquiring and commercializing products that address unmet therapeutic needs in arthritis, pain, inflammatory and orphan diseases.
The company operates through three business units – Orphan, Primary Care and Rheumatology. Its portfolio currently comprises nine marketed products. Key products include Actimmune (chronic granulomatous disease and severe malignant osteopetrosis) and Duexis (signs and symptoms of osteoarthritis and rheumatoid arthritis) among others.
The company has been actively pursuing acquisitions to expand and diversify its portfolio. In this scenario, investor focus remains on the company’s performance apart from the usual top-and bottom-line numbers.
Horizon beat earnings estimates by 31.82% in the last quarter. Overall, Horizon has beaten earnings estimates thrice in the four quarters with an average positive surprise of 68.92%. Currently, Horizon Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Horizon Pharma’s first-quarter 2018 earnings missed expectations. Our consensus called for EPS of 11 cents, and the company reported EPS of 3 cents.
Revenues: Revenues in the reported quarter also missed expectations. Horizon Pharma posted revenues of $223.9 million which is below our consensus estimate of $239.45 million.
Key Stats: The company’s revenues was mainly driven by growth in its rheumatology and orphan business units, with sales of Krystexxa and Ravicti rising 48% and 12%. However, sales from primary care business unit declined due to the implementation of the new contracting model with pharmacy benefit managers. The company announced a realigning of operating structure and will present its financial result under two segments – strategic rare disease-focused business and the primary care segment – starting from the second quarter of 2018.
2018 Outlook: The company provided its outlook for 2018 and expects sales in the range of $1.17 billion to $1.2 billion in 2018. Horizon Pharma expects Krystexxa to continue its performance with the drug’s sales expect to grow more than 65% in 2018.
Pre-Market Trading: Shares were inactive in pre-market trading.
Check back later for our full write up on this HZNP earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Image: Bigstock
Horizon Pharma (HZNP) Q1 Loss Wider, Revenues Miss
Dublin, Ireland-based Horizon Pharma plc is a biopharmaceutical focused on identifying, developing, acquiring and commercializing products that address unmet therapeutic needs in arthritis, pain, inflammatory and orphan diseases.
The company operates through three business units – Orphan, Primary Care and Rheumatology. Its portfolio currently comprises nine marketed products. Key products include Actimmune (chronic granulomatous disease and severe malignant osteopetrosis) and Duexis (signs and symptoms of osteoarthritis and rheumatoid arthritis) among others.
The company has been actively pursuing acquisitions to expand and diversify its portfolio. In this scenario, investor focus remains on the company’s performance apart from the usual top-and bottom-line numbers.
Horizon beat earnings estimates by 31.82% in the last quarter. Overall, Horizon has beaten earnings estimates thrice in the four quarters with an average positive surprise of 68.92%. Currently, Horizon Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Horizon Pharma’s first-quarter 2018 earnings missed expectations. Our consensus called for EPS of 11 cents, and the company reported EPS of 3 cents.
Revenues: Revenues in the reported quarter also missed expectations. Horizon Pharma posted revenues of $223.9 million which is below our consensus estimate of $239.45 million.
Key Stats: The company’s revenues was mainly driven by growth in its rheumatology and orphan business units, with sales of Krystexxa and Ravicti rising 48% and 12%. However, sales from primary care business unit declined due to the implementation of the new contracting model with pharmacy benefit managers. The company announced a realigning of operating structure and will present its financial result under two segments – strategic rare disease-focused business and the primary care segment – starting from the second quarter of 2018.
2018 Outlook: The company provided its outlook for 2018 and expects sales in the range of $1.17 billion to $1.2 billion in 2018. Horizon Pharma expects Krystexxa to continue its performance with the drug’s sales expect to grow more than 65% in 2018.
Pre-Market Trading: Shares were inactive in pre-market trading.
Check back later for our full write up on this HZNP earnings report later!
Horizon Pharma Public Limited Company Price and EPS Surprise
Horizon Pharma Public Limited Company Price and EPS Surprise | Horizon Pharma Public Limited Company Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>